Two additional active clinical trials are ongoing to investigate ROR2-specific CAR T cells in ROR2-positive renal cell carcinomas (NCT03393936) and ROR2 expressing solid malignancies (NCT03960060). Here, ROR2 is linked to hereditary clear cell renal cell carcinoma.